GENE ONLINE|News &
Opinion
Blog

2024-02-23| TechnologyTrending

Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech

by Oscar Wu
Share To

Graphics Processing Units (GPUs) have become increasingly instrumental in advancing life science research due to their ability to perform rapid parallel processing. In the field of bioinformatics, GPUs can accelerate research with a typical speedup of two orders of magnitude, especially beneficial for high-throughput tasks that involve floating operations, parallelism, and energy efficiency. 

One study evaluated acceleration for life science applications, including the Markov Random Fields-based (MRF) liver segmentation and HMMER’s Viterbi algorithm, showcasing its potential for complex biological image processing and sequence analysis.

The Benefits and Challenges of Parallel Architectures for Life Sciences

GPUs have also played a substantial role in accelerating various bioinformatics tools over the past two to three decades, enabling computational analysis in different life science disciplines. 

The review highlights the advantages and limitations of using parallel architectures. In terms of image processing, GPU-accelerated libraries, such as CLIJ, facilitate batch processing of large amounts of image data at high speeds, furthering the capabilities of life science applications. 

An evaluation of life science algorithms for novel GPU architectures revealed that some computational tasks like Direct Coulomb Summation are particularly well-suited to GPU computing, outperforming traditional methods like Needleman-Wunsch sequence alignment in efficiency.

Transforming Next-Generation Sequence Analysis

GPU technology enables impressive performance enhancements in sequence alignment within bioinformatics, achieving speedups around 120X using dynamic and concurrent kernel features alongside tiling techniques. 

Similarly, molecular dynamics applications such as Gromacs have shown 2-3 times speedup on GPU platforms compared to multi-core CPUs, indicating favorable scaling behavior for life science computations. 

Another study examining GPU-accelerated DNA sequence alignment tools reported the potential for speeding up next-generation sequence analysis by 2x to 10x over traditional CPU-based tools.

Accelerating Drug Discovery with Molecular Docking

In molecular docking, a pivotal technique in drug discovery, GPU technology can significantly reduce computation times through its general-purpose computing capabilities, which enable effective parallelization.

The development of a GPU-based streamline pruning algorithm has achieved more than 100× speedups in generating brain connectomes for big data applications.

GPU technology has also shown promise in enhancing the speed and predictability of complex computational models in cyber-physical systems.

The Synergy of GPUs and TPUs for Life Science AI Advancement

GPUs are not only utilized in bioinformatics and computational biology but have also found applications in training and inference acceleration of artificial intelligence (AI) models such as neural networks in life science research, with both GPUs and TPUs being commonly used as AI accelerators. 

These examples demonstrate the versatility and transformative impact of GPU technology across various life science domains, contributing to an acceleration of scientific discovery and innovation.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Neurosurgery Now: NVIDIA’s Holoscan AI Brings Real-Time 3D Vision to Enhance Surgical Precision at 2025 GTC
2025-03-18
NVIDIA GTC 2025: BioMap’s xTrimo — The AI Model That’s Changing Biotech and Drug Discovery
2025-03-18
What is Tech Giant NVIDIA Doing Now? Latest Collabs Building the Healthcare Puzzle, One Byte at a Time
2025-01-15
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top